Veradermics reported cash from operations of -$14.50M and free cash flow of -$14.58M for the quarter ended Jun 2026. This cash flow statement covers 4 quarters of results from Mar 2025 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Mar2025 | Jun2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|
| Operating Activities | ||||
| Net Income | -12.40M | -15.64M | -27.23M | -23.50M |
| Share-based Compensation | 0.21M | 0.12M | 5.26M | 3.52M |
| Change in Interest Receivables | 1.50M | 1.28M | ||
| Cash from Operations | -13.32M | -15.68M | -21.20M | -14.50M |
| Depreciation, Depletion & Amortization | ||||
| Amortizatization of Intangibles | 0.01M | 0.23M | 0.07M | -0.00M |
| Change in Working Capital | ||||
| Change in Account Payables | -0.69M | -1.03M | -1.05M | 4.85M |
| Change in Accured Expenses | -0.86M | 1.56M | -1.37M | -0.21M |
| Other Working Capital Changes | -0.08M | 0.89M | -4.36M | -1.42M |
| Investing Activities | ||||
| Capital Expenditures | 0.02M | 0.17M | 0.08M | |
| Change in Acquisitions & Divestments | 21.69M | 28.31M | ||
| Cash from Investing Activities | -15.75M | -8.33M | -101.30M | -277.29M |
| Financing Activities | ||||
| Other financing activities | 0.13M | 269.10M | ||
| Misc. | ||||
| Cash from Financing Activities | 8.42M | 0.13M | 269.11M | 442.70M |
| Change in Cash | -20.64M | -23.84M | 146.65M | 150.92M |
| Free Cash Flow | -13.34M | -15.68M | -21.37M | -14.58M |
| Net Cash Flow | -20.64M | -23.88M | 146.61M | 150.91M |